In a report released today, Andrew Berens from Leerink Partners downgraded Boundless Bio Inc. (BOLD – Research Report) to a Hold, with a price target of $3.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Andrew Berens has given his Hold rating due to a combination of factors affecting Boundless Bio Inc.’s current strategic direction. The company has decided to discontinue its current monotherapy and combination arms of the BBI-355 (CHK1) program due to a narrow therapeutic index and observed hematologic toxicity at doses necessary for clinical activity. This decision marks a significant setback as it necessitates a return to proof-of-principle and dose-optimization efforts, which could delay progress.
Furthermore, the anticipated validation of the ecDNA hypothesis using the ECHO diagnostic tool has been postponed, leaving the investment thesis uncertain until new developments, such as the BBI-940 asset, are realized. The shift in strategy, along with the delays in key program validations, has led to a reassessment of the company’s potential, resulting in a Hold rating as the company navigates these challenges.